MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 09-05-2025
Phreesia EBITDA 2011-2025 | PHR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Phreesia
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107 M | -151 M | -95.5 M | -9.76 M | -1.37 M | 2.1 M | -4.91 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.1 M | -151 M | -52.5 M |
Quarterly EBITDA Phreesia
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | 3.59 M | -6.76 M | -9.92 M | -12.7 M | -24.6 M | -32.7 M | -30.9 M | - | -34.9 M | -42.1 M | -44.7 M | - | -20.3 M | -13.6 M | -5.7 M | -4.67 M | 5.54 M | 1.35 M | -1.34 M | -3.3 M | 8.04 M | 2.65 M | -881 K | - | -1.07 M | 528 K | -1.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.04 M | -44.7 M | -10.6 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Covetrus
CVET
|
148 M | - | - | $ 2.94 B |  USA |
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Accolade
ACCD
|
-38.6 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 4.15 | 0.24 % | $ 389 M | USA |
 |
Health Catalyst
HCAT
|
-28.4 M | $ 2.43 | 2.1 % | $ 146 M | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 23.69 | -0.59 % | $ 720 M | USA |
 |
MTBC
MTBC
|
23.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
Akerna Corp.
KERN
|
-6.57 M | - | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
271 M | $ 93.67 | 1.32 % | $ 8.01 B | USA |
 |
American Well Corporation
AMWL
|
-185 M | $ 4.59 | 0.44 % | $ 68.8 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 12.53 | -1.8 % | $ 215 M | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.76 | -0.36 % | $ 1.06 B | USA |
 |
So-Young International
SY
|
-579 M | $ 2.65 | -5.54 % | $ 210 M |  China |
 |
Progyny
PGNY
|
19 M | $ 25.95 | 1.72 % | $ 2.23 B | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 46.4 | 1.34 % | $ 2.14 B | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
Premier
PINC
|
119 M | $ 28.26 | - | $ 2.33 B | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
-110 K | $ 0.48 | -9.76 % | $ 2.5 M | China |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
Schrödinger
SDGR
|
-203 M | $ 18.38 | - | $ 1.34 B | USA |
 |
Signify Health
SGFY
|
63.3 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
-658 M | $ 7.12 | -1.66 % | $ 1.21 B | USA |
 |
10x Genomics
TXG
|
-230 M | $ 16.61 | -0.51 % | $ 1.95 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
435 M | $ 224.44 | 0.51 % | $ 36 B | USA |
 |
SCWorx Corp.
WORX
|
-1.26 M | $ 0.2 | 0.3 % | $ 292 K | USA |